ReposiTrak (TRAK) Q4 2026 Earnings Call Transcript

ReposiTrak (TRAK) reported full-year 2026 results showing revenue of $23.3 million, up 3% from $22.6 million, alongside recurring revenue growth of 4% as the company continued shifting toward SaaS. Operating expenses fell 6% to $15.4 million, lifting operating margin to 33.7%, up 620 basis points from 27.5%. Net income rose to $7.6 million and diluted EPS reached $0.39. In Q4, revenue was $5.6 million, down 3%, while GAAP net income increased 16% to $2.1 million. Cash stood at $27.3 million as of June 30, 2026, with buybacks and a $0.02 quarterly dividend per share. The FDA traceability compliance date is July 20, 2028, after an extension from Jan. 20, 2026.